
Dec 22 (Reuters) - Viridian Therapeutics Inc VRDN.O:
VIRIDIAN THERAPEUTICS ANNOUNCES BLA ACCEPTANCE AND PRIORITY REVIEW FOR VELIGROTUG FOR THE TREATMENT OF THYROID EYE DISEASE
VIRIDIAN THERAPEUTICS INC - PDUFA TARGET ACTION DATE SET FOR JUNE 30, 2026
VIRIDIAN THERAPEUTICS INC - PLANS TO SUBMIT MARKETING AUTHORIZATION APPLICATION TO EMA IN Q1 2026